Lysophosphatidate Signaling: The Tumor Microenvironment's New Nemesis

Trends Cancer. 2017 Nov;3(11):748-752. doi: 10.1016/j.trecan.2017.09.004. Epub 2017 Oct 2.

Abstract

Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating chronic inflammation, irrespective of diverse mutations within cancer cells.

Keywords: autotaxin; chemoresistance; lipid phosphate phosphatases; lysophosphatidic acid; metastasis; radiotherapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Inflammation / genetics
  • Inflammation / pathology
  • Lysophospholipids / genetics*
  • Multienzyme Complexes / genetics
  • Mutation
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Phosphodiesterase I / genetics
  • Signal Transduction / genetics
  • Tumor Microenvironment / genetics*

Substances

  • Lysophospholipids
  • Multienzyme Complexes
  • Phosphodiesterase I
  • lysophosphatidic acid